Cost Estimation of Cardiovascular Disease Events in the US

O’Sullivan, Amy K.; Rubin, J.L.; Nyambose, Joshua; Kuznik, Andreas; Cohen, David J.; Thompson, David R.

doi:10.2165/11584620-000000000-00000

Cited by 76 publications

(63 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…95,96 Cost-Effectiveness of Therapy Both the acute and long-term costs associated with cardiovascular events are high. [97][98][99][100] For example, in a managed care setting, the total first-year health care cost per patient after acute coronary syndrome was estimated at $22,529. 97 In another managed care study, the total average annualized health care costs for the treatment of peripheral artery disease was $5,955.…”

Section: Management Of Familial Hypercholesterolemia: a Review Of Thementioning

confidence: 99%

“…Furthermore, the cost-effectiveness of statins will generally continue to decrease as the patents for these drugs expire. 99 Indeed, over a longer-term period of treatment of more than 10 years, generic high-intensity statin therapy to lower LDL-C levels by 50% is more cost-effective than lower doses of statins in primary prevention in those without FH. 101 As previously levels was observed; however, adverse effects included increased aminotransferase levels and fat in the liver.…”

Section: Management Of Familial Hypercholesterolemia: a Review Of Thementioning

confidence: 99%

See 1 more Smart Citation

Management of Familial Hypercholesterolemia: A Review of the Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Robinson

2013

JMCP

View full text Add to dashboard Cite

suMMaRyFamilial hypercholesterolemia (FH) is a genetic disorder of lipid metabolism that is characterized by a significant elevation in levels of low-density lipoprotein cholesterol (LDL-C), and patients are at very high risk for premature coronary heart disease (CHD). The etiology of FH includes known mutations in the gene of the LDL receptor, LDLR ; the gene of apolipoprotein B, apo B ; and the proprotein convertase subtilisin/kexin type 9 gene, PCSK9. The National Lipid Association Expert Panel on Familial Hypercholesterolemia has provided recommendations for the screening and treatment of patients with FH. Early identification and aggressive treatment of FH in individual patients, as well as screening of all first-degree relatives, are recommended to minimize the risk for premature CHD. Similar to patients with conventional hypercholesterolemia, patients with FH should receive statins as initial treatment, but patients with FH may require higher doses of statins, more potent statins, statin-based combination therapy, or adjunctive therapies. Patients with FH who have additional risk factors for, or existing, cardiovascular disease or those with an inadequate response to initial statin therapy should have access to higher doses of the most efficacious statins; statins used in combination with other LDL-C-lowering agents should also be supported by formularies; additional treatments, such as LDL-C apheresis or novel therapies, may also be required to achieve acceptable LDL-C levels. New treatment approaches include mipomersen, which was approved by the FDA in January 2013. Mipomersen is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis (called an antisense inhibitor) indicated as an adjunct to lipid-lowering medications and diet to reduce LDL-C, apolipoprotein B, total cholesterol, and non-high density lipoproteincholesterol (non-HDL-C) levels in patients with homozygous FH (HoFH). The microsomal transfer protein lomitapide has also received FDA approval for use only in patients with HoFH. Other novel treatments currently in development include PCSK9 inhibitors. Therapies such as apheresis are likely more expensive than simple therapy with a statin but may be needed to achieve long-term reductions in complications from nonfatal and fatal cardiovascular events and hospitalizations related to myocardial infarction, cardiac revascularization, and stroke in FH patients. The cost-effectiveness of this more aggressive therapy has not been determined and should be studied. Utilization of published guidelines and the recommendations from the National Lipid Association will help to optimize the management of patients with FH.

show abstract

Section: Management Of Familial Hypercholesterolemia: a Review Of Thementioning

confidence: 99%

Section: Management Of Familial Hypercholesterolemia: a Review Of Thementioning

confidence: 99%

Management of Familial Hypercholesterolemia: A Review of the Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Robinson

2013

JMCP

View full text Add to dashboard Cite

show abstract

“…It is also interesting to compare the costs of psychiatric hospitalization to those for common general medical disorders. For example, recent cost-estimates of hospitalization for stroke have averaged 21.8 (CI: 4.70-39.0), and for a heart attack or comparable cardiac illness, 27.3 (8.75-35.8) thousands of US dollars, or 2.3-2.9-times more than the average cost of psychiatric hospitalization at the present study site, 9.50 (8.86-10.1) [58][59][60].…”

Section: Discussionmentioning

confidence: 63%

Factors Associated with Costs of Hospitalization of Severely Mentally Ill Patients

Curto¹,

Masters²,

Girardi³

et al. 2016

Bipolar Disord

View full text Add to dashboard Cite

“…Costs associated with stroke and myocardial infarction were estimated from a recent analysis of a large managed care population in the United States and other published sources (22)(23)(24). Costs of CEA were estimated from Medicare payments from the Healthcare Cost and Utilization Project Nationwide Inpatient Sample (21).…”

Section: Costs and Health-related Quality Of Lifementioning

confidence: 99%

Cost-Effectiveness of Carotid Plaque MR Imaging as a Stroke Risk Stratification Tool in Asymptomatic Carotid Artery Stenosis

et al. 2015

View full text Add to dashboard Cite

Cost Estimation of Cardiovascular Disease Events in the US

Abstract: This study provides updated estimates of medical care costs of cardiovascular events among a managed care population over various time horizons. Results suggest that the economic burden of cardiovascular disease is substantial, both in the acute phase as well as over the longer term.

Cited by 76 publications

References 24 publications

Management of Familial Hypercholesterolemia: A Review of the Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Management of Familial Hypercholesterolemia: A Review of the Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Factors Associated with Costs of Hospitalization of Severely Mentally Ill Patients

Cost-Effectiveness of Carotid Plaque MR Imaging as a Stroke Risk Stratification Tool in Asymptomatic Carotid Artery Stenosis

Contact Info

Product

Resources

About